Clinical medicine

Insight Global Announces 'Jobs & Joy'

Retrieved on: 
Tuesday, October 27, 2020
Anatomical pathology, Hematology, Lymphoma, Hodgkin lymphoma, Clinical medicine, Health, Medicine

ATLANTA, Oct. 27, 2020 /PRNewswire/ --Starting next Monday, Insight Global is pledging to put 8,000 people to work over eight weeks between November 2and December 25.

Key Points: 
  • ATLANTA, Oct. 27, 2020 /PRNewswire/ --Starting next Monday, Insight Global is pledging to put 8,000 people to work over eight weeks between November 2and December 25.
  • Together, alongside their consultants andcustomers, Insight Global will make a difference for not only 8,000 job-seekers, but will also make a difference for eightcharities within their communities.
  • For every 100th hire, Insight Global will donate $1,000 to one of eightpre-selected charities chosen by both the consultant and the customer ($500 per person).
  • https://oneworldhealth.com
    Mission statement:"THE LLS MISSION:Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families."

Kugler Vision to Implant New Vivity IOL for Cataracts

Retrieved on: 
Tuesday, October 27, 2020
Clinical medicine, Eye surgery, Medical specialties, Medicine, Vision, Ophthalmology, Eye, Refraction, Refractive surgery, Cataract, Cataract surgery

On Tuesday, Oct. 27, Lance Kugler, MD, of Kugler Vision in Omaha, Nebraska, will be the first surgeon in eastern Nebraska to use the AcrySof IQ Vivity Lens (IOL).

Key Points: 
  • On Tuesday, Oct. 27, Lance Kugler, MD, of Kugler Vision in Omaha, Nebraska, will be the first surgeon in eastern Nebraska to use the AcrySof IQ Vivity Lens (IOL).
  • The Vivity Extended Vision IOL, approved by the FDA in the spring of 2020, offers an extended range of vision for cataract patients, and reduces the need for vision aids in their daily life post-procedure.
  • The Vivity lens gives the patient freedom from cataracts and the opportunity to live a rich and active lifestyle with less reliance on glasses.
  • Kugler Vision is a world-class refractive surgery center making Omaha, Nebraska, a destination for exceptional vision correction outcomes.

Cytocom Strategic Vision Conference Call Reminder

Retrieved on: 
Tuesday, October 27, 2020
Medical specialties, Clinical medicine, Medicine, Autoimmune diseases, Cleveland BioLabs, Fibromyalgia, Crohn's disease

ET, to discuss the proposed merger with Cleveland BioLabs (CBLI) and provide a strategic vision for the combined company.

Key Points: 
  • ET, to discuss the proposed merger with Cleveland BioLabs (CBLI) and provide a strategic vision for the combined company.
  • Interested participants and investors may access the conference call by dialing:
    The conference call can also be accessed at https://cleartrustonline.com/cytocom .
  • Approximately two hours following the live event, a webcast replay of the conference call will be available on Cytocom's website https://www.cytocom.com/investors/ for approximately 30 days.
  • Specifically, Cytocom has four programs in late-stage clinical development in Crohn's disease, fibromyalgia, multiple sclerosis and pancreatic cancer.

UPDATE: BetterLife CEO Highlights Crucial Difference Between the Company’s Interferon Alpha 2b and Synairgen PLC’s Interferon Beta

Retrieved on: 
Wednesday, October 28, 2020
Cytokines, Antivirals, Interferon, Branches of biology, Clinical medicine, Medicine, Interferon beta-1a

NEW YORK CITY, Oct. 28, 2020 (GLOBE NEWSWIRE) -- UPDATE: BetterLife CEO Highlights Crucial Difference Between the Companys Interferon Alpha 2b and Synairgen PLCs Interferon Beta

Key Points: 
  • NEW YORK CITY, Oct. 28, 2020 (GLOBE NEWSWIRE) -- UPDATE: BetterLife CEO Highlights Crucial Difference Between the Companys Interferon Alpha 2b and Synairgen PLCs Interferon Beta
    The Chief Executive Officer for BetterLife Pharma Inc. (OTCQB:BETRF) (CSE:BETR), an emerging biotechnology company currently preparing for clinical trials of AP-003, its interferon alpha 2b COVID-19 treatment, joined investor portalProactiveto discuss the key differences between the interferon inhalation formula used by BetterLife against that used successfully by Synairgen PLC.
  • The Synairgen trials caused much excitement, strongly demonstrating that treatments using an interferon beta inhalation in COVID-19 patients significantly improved their condition and sped up recovery.
  • BetterLife is due to start its clinical trials later this fall in Australia for AP-003, BetterLifes inhaled human interferon alpha 2b, in patients with mild to moderate symptoms of COVID-19.
  • While both AP-003 and interferon beta are hypothesized to bypass the COVID-19 induced interferon production blockade, BetterLife believe that their proprietary inhaled alpha 2b (exclusively owned and developed by the Company) could be much more effective against the severity and duration of COVID-19 than interferon beta.

ALX Oncology Announces First Patient Dosed in ASPEN-02, a Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome

Retrieved on: 
Wednesday, October 28, 2020
Cancer treatments, Drugs, Clinical medicine, Prodrugs, Antibody-drug conjugates, Monoclonal antibodies, Antineoplastic drugs, Evofosfamide, Organobromides, Vadastuximab talirine

The Phase 1 part of the study is expected to characterize the safety of ALX148 in combination with azacitidine in patients with relapsed/refractory or previously untreated higher-risk MDS.

Key Points: 
  • The Phase 1 part of the study is expected to characterize the safety of ALX148 in combination with azacitidine in patients with relapsed/refractory or previously untreated higher-risk MDS.
  • Upon completion of the Phase 1, the Phase 2 component of the study will be initiated to evaluate the efficacy of the combination in patients with previously untreated higher-risk MDS.
  • ALX148 was designed for use in combination with a range of agents to maximize anti-cancer activity while minimizing associated toxicity.
  • This study builds upon the compelling combination activity observed in patients with ALX148 and multiple other anti-cancer agents, said Sophia Randolph, M.D., Ph.D., Chief Medical Officer of ALX Oncology.

Basilea announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ramucirumab in the ongoing FIDES-03 study with derazantinib in gastric cancer

Retrieved on: 
Wednesday, October 28, 2020
Clinical medicine, Drugs, Medicine, Monoclonal antibodies, Ramucirumab, Breakthrough therapy, Cancer immunotherapy, Orphan drugs, Atezolizumab, Checkpoint inhibitor, Angiogenesis inhibitor, PD-L1

Basilea is the sponsor of the study and Lilly will collaborate on clinical aspects and provide clinical supply of ramucirumab.

Key Points: 
  • Basilea is the sponsor of the study and Lilly will collaborate on clinical aspects and provide clinical supply of ramucirumab.
  • The FIDES-03 study will assess the efficacy and safety of derazantinib as monotherapy and combination therapy with ramucirumab and paclitaxel or with Roches PD-L1 checkpoint inhibitor atezolizumab.
  • Dr. Marc Engelhardt, Chief Medical Officer, said: The agreement with Lilly allows us to investigate the potential of derazantinib combined with ramucirumab and paclitaxel, which is the standard of care in the second-line treatment of gastric cancer.
  • Its unique kinase inhibition profile may complement the anti-angiogenic effects of ramucirumab in the treatment of patients with advanced gastric cancer.

ENHERTU® Granted Priority Review in the U.S. for Treatment of HER2 Positive Metastatic Gastric Cancer

Retrieved on: 
Wednesday, October 28, 2020
Oncology, Health, Genetics, Other Health, Clinical trials, Pharmaceutical, Clinical medicine, Medicine, Breakthrough therapy, Antineoplastic drugs, Cancer treatments, Daiichi Sankyo, Trastuzumab deruxtecan, HER2/neu, Metastatic breast cancer, Breast cancer, Trastuzumab emtansine, Tucatinib, Gastric Cancer, DESTINY-Gastric01, ENHERTU, the ENHERTU Clinical Development Program, the Collaboration between Daiichi Sankyo and AstraZeneca, Daiichi Sankyo Cancer Enterprise, Daiichi Sankyo

Once patients with HER2 positive metastatic gastric cancer progress following initial treatment with an anti-HER2 regimen, there are no approved HER2 directed medicines, said Jos Baselga, MD, PhD, Executive Vice President, Oncology R&D, AstraZeneca.

Key Points: 
  • Once patients with HER2 positive metastatic gastric cancer progress following initial treatment with an anti-HER2 regimen, there are no approved HER2 directed medicines, said Jos Baselga, MD, PhD, Executive Vice President, Oncology R&D, AstraZeneca.
  • ENHERTU (5.4 mg/kg) is approved in the U.S. and Japan for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting based on the DESTINY-Breast01 trial, and is under accelerated assessment in the European Union for HER2 positive metastatic breast cancer.
  • Recently, in September 2020, ENHERTU (6.4 mg/kg) was approved in Japan for patients with HER2 positive unresectable advanced or recurrent gastric cancer that has progressed after chemotherapy.
  • Two additional phase 2 trials DESTINY-Gastric02 and DESTINY-Gastric03 are underway further evaluating the use of ENHERTU in patients with HER2 positive metastatic gastric cancer.

NOXXON Announces Completion of 6-month Therapy for Low-dose Cohort in Phase 1/2 Brain Cancer Study of NOX-A12 Plus Radiotherapy

Retrieved on: 
Wednesday, October 28, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Medicine, Clinical medicine, Health, Oncology, Medical physics, Radiobiology, Noxxon Pharma, Brain tumor, Chemotherapy, Pancreatic cancer, Cancer, Radiation therapy

Going forward NOXXONs planned clinical development strategy for NOX-A12 will be focused on two indications: brain cancer and pancreatic cancer.

Key Points: 
  • Going forward NOXXONs planned clinical development strategy for NOX-A12 will be focused on two indications: brain cancer and pancreatic cancer.
  • Each indication will test a different combination strategy, thereby providing multiple possibilities to successfully advance the clinical development plan: NOX-A12 plus radiotherapy in brain cancer, and NOX-A12 plus immuno-/chemotherapy in pancreatic cancer.
  • In brain cancer, NOXXON plans to complete the ongoing Phase 1/2 study testing three doses of NOXA12 combined with radiotherapy.
  • In September 2019 the company initiated an additional trial with NOX-A12 in brain cancer in combination with radiotherapy.

Aurinia Announces European Investigator-Initiated Trial to Evaluate Antiviral Activity of Voclosporin in Kidney Transplant Recipients with COVID-19

Retrieved on: 
Tuesday, October 27, 2020
Research, Infectious diseases, Hospitals, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Medical specialties, Clinical medicine, Medicine, Organ transplantation, Immunosuppressants, Transplantation medicine, Macrolides, Astellas Pharma, Tacrolimus, Kidney transplantation, Immunosuppressive drug, Transplant rejection, the VOCOVID Study, Voclosporin, Leiden University Medical Center, Aurinia

Onno Teng at the Leiden University Medical Center (LUMC) in the Netherlands and will compare voclosporin against tacrolimus.

Key Points: 
  • Onno Teng at the Leiden University Medical Center (LUMC) in the Netherlands and will compare voclosporin against tacrolimus.
  • Organ transplant recipients who contract COVID-19 are at greater risk for complications due to the requirement of daily immunosuppressive medications to prevent organ rejection.
  • In contrast to voclosporin, tacrolimus did not show antiviral activity against SARS-CoV-2 in vitro at clinically relevant concentrations.
  • This 56-day open-label investigator initiated trial (IIT) is designed to evaluate the antiviral effects of voclosporin compared to tacrolimus in stable kidney transplant recipients (KTRs) who contracted SARS-CoV-2.

Hereditary Angioedema R&D Pipeline Analysis Report, Q4 2020 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 27, 2020
Health, Hospitals, Other Health, Managed care, General Health, Biotechnology, Complement deficiency, Medical specialties, Angioedema, Hereditary angioedema, Clinical medicine, Acquired C1 esterase inhibitor deficiency

The "Hereditary Angioedema R&D Pipeline Analysis Report, Q4 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hereditary Angioedema R&D Pipeline Analysis Report, Q4 2020" report has been added to ResearchAndMarkets.com's offering.
  • The comprehensive report on the indication presents Hereditary Angioedema disease overview, Hereditary Angioedema types, Hereditary Angioedema symptoms, causes, and FDA/EMA approved treatment options.
  • The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Hereditary Angioedema indication.
  • Further, the presence of large companies and stringent regulations act as barriers for Hereditary Angioedema pipeline development companies.